Baidu
map

“上下协同,构建系统” -- 2018年医药商业创新年会即将在沪举办

2018-10-26 美通社 美通社

2018年12月11日-13日,思齐俱乐部(以下简称思齐)将在上海举办2018年医药商业创新年会,将邀请来自内外资药企的商务部门高管,以及医药创新公司和一些MNC及CSO的公司,就医药流通行业政策解读、模式创新等话题共同展开讨论。2018年12月11日-13日,思齐俱乐部将在上海举办2018年医药商业创新年会,将邀请来自内外资药企的商务部门高管,以及医药创新公司和一些MNC及CSO的公司,就医药流

2018年12月11日-13日,思齐俱乐部(以下简称思齐)将在上海举办2018年医药商业创新年会,将邀请来自内外资药企的商务部门高管,以及医药创新公司和一些MNC及CSO的公司,就医药流通行业政策解读、模式创新等话题共同展开讨论。

2018年12月11日-13日,思齐俱乐部将在上海举办2018年医药商业创新年会,将邀请来自内外资药企的商务部门高管,以及医药创新公司和一些MNC及CSO的公司,就医药流通行业政策解读、模式创新等话题共同展开讨论。

此次大会主题为“一致性评价后市场新格局”,将从医药商业创新热点出发,就CSO模式系统化建设、市场策略及学术推广、代理招商和销售效率、政策解读和财务法规等方面,剖析和交流医药商业创新的核心主题。

在大会期间,思齐还将邀请国内外的新研产品进行现场发布,设立展示墙,组织CSO公司开展现场路演,建立供需信息互通群组系统,以多种形式促进医药商业共同实现“上下协同,构建系统”的共赢目标。

会议将共设置CSO模式、市场策略、学术推广、代理招商、政策解读和财务法规6大演讲主题及5场圆桌论坛,以及产品信息发布交流墙,为与会者提供多样化的技术交流、商务洽谈以及合作对接的桥梁。

此次会议,旨在聚集医药商业各上下游,共同探讨国内医药流通行业未来的发展创新之道,共同促进国内医药行业的进步。

2018年商业年会参会嘉宾单位汇总 
2018年商业年会参会嘉宾单位汇总

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771785, encodeId=3bd11e717858b, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Jan 16 10:09:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285647, encodeId=2e5d128564eaa, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Oct 28 00:09:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409702, encodeId=8d001409e025b, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 28 00:09:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535073, encodeId=94c315350e34b, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sun Oct 28 00:09:00 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1771785, encodeId=3bd11e717858b, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Jan 16 10:09:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285647, encodeId=2e5d128564eaa, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Oct 28 00:09:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409702, encodeId=8d001409e025b, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 28 00:09:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535073, encodeId=94c315350e34b, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sun Oct 28 00:09:00 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1771785, encodeId=3bd11e717858b, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Jan 16 10:09:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285647, encodeId=2e5d128564eaa, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Oct 28 00:09:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409702, encodeId=8d001409e025b, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 28 00:09:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535073, encodeId=94c315350e34b, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sun Oct 28 00:09:00 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
    2018-10-28 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1771785, encodeId=3bd11e717858b, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Jan 16 10:09:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285647, encodeId=2e5d128564eaa, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Oct 28 00:09:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409702, encodeId=8d001409e025b, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 28 00:09:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535073, encodeId=94c315350e34b, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sun Oct 28 00:09:00 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map